Global Gastrointestinal Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026

Gastrointestinal disorders are related to digestive system and generally affect the colon, small & large intestine and rectum. The disorders include constipation, peptic ulcer diseases and irritable bowel syndrome. The major reason and cause of GI disorders are stress, intake of medicines such as iron pills and anti-depressants and unhealthy eating habits. Symptoms of the gastrointestinal infections include pain, bloating, diarrhea, nausea and vomiting. The major drugs that dominate the gastrointestinal diagnostics and therapeutics market are aciphex, afinitor, akynzeo, dificid and Prilosec.

Market Analysis and Insights: Global Gastrointestinal Therapeutics and Diagnostics Market
The global Gastrointestinal Therapeutics and Diagnostics market size is projected to reach US$ 49890 million by 2026, from US$ 48610 million in 2020, at a CAGR of 2.4%% during 2021-2026.

Global Gastrointestinal Therapeutics and Diagnostics Scope and Market Size
Gastrointestinal Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study

Abbott Laboratories
AstraZeneca
Eisai
Johnson & Johnson
Salix Pharmaceuticals
Takeda Pharmaceutical Company
...

Market segment by Type, the product can be split into

Diagnostics
Therapeutics

Market segment by Application, split into

Gastroenteritis
GI Bleeding
Irritable Bowel Syndrome
Peptic Ulcer Disease (PUD)
Others

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India

Frequently Asked Questions